These observations are consistent with previous publications showing that tumor-derived CD11bGr+ cells promote the de novo differentiation of Treg cells in prostate cancer models and reduce circulating IFN-γ-producing T cells in B cell malignancies (Bezzi et al., 2018, Christopoulos et al., 2011). This evidence concerns the gene IFNG and prostate carcinoma.